Pharmaceutical Investing CASI Pharmaceuticals Receives Extension from Nasdaq to Meet Listing Requirements
Pharmaceutical Investing CASI Pharmaceuticals Announces Results from CID-103 Immune Thrombocytopenia Study at the 67th American Society of Hematology Annual Meeting
Pharmaceutical Investing CASI Pharmaceuticals Announces Third Quarter 2025 Business and Financial Results
Pharmaceutical Investing CASI Pharmaceuticals Receives and Appeals Delisting Determination from NASDAQ
